<DOC>
	<DOCNO>NCT01409473</DOCNO>
	<brief_summary>The purpose study determine whether stereotactic body radiation therapy ( SBRT ) simultaneous boost ( high radiation dose ) area within prostate prominent cancerous growth ( intraprostatic lesion ) utilize intensity modulate radiotherapy ( IMRT ) plan technique safe effective treatment patient low- intermediate-risk localized prostate cancer .</brief_summary>
	<brief_title>Stereotactic Body Radiotherapy ( SBRT ) With Concurrent Boost Low- Intermediate-Risk Prostate Cancer</brief_title>
	<detailed_description>Standard external beam radiation therapy ( EBRT ) low- intermediate-risk prostate cancer involve several week daily treatment session . Stereotactic body radiation therapy ( SBRT ) new form EBRT give few treatment higher dos radiation per treatment . In many patient certain area within prostate prominent cancerous growth ( intraprostatic lesion ) , may require high dos radiation ( boost ) treat effectively . This study treat prostate simultaneous boost ( ) intraprostatic lesion ( ) 5 treatment 10-14 day .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically proven diagnosis prostate adenocarcinoma within one year Gleason Score 27 Clinical Tstage T1bT2c ( AJCC 7th Edition ) Clinical Nx N0 , Mx M0 PSA &lt; 20 ng/mL Low intermediate risk accord NCCN guideline : Low : Clinical Stage ( CS ) T1bT2a Gleason 26 PSA &lt; 10 ng/ml ; Intermediate : CS T2bT2c Gleason 26 PSA &lt; 10 ng/ml , CS T1bT2a Gleason 7 PSA &lt; 10 ng/ml , CS T1bT2a Gleason 26 PSA 1020ng/mL ECOG performance status 0 1 Has pretreatment PSA drawn within month begin protocol therapy If androgendeprivation therapy ( ADT ) initiate , must document preADT PSA ; baseline PSA obtain follow period : 1 ) 10day period follow prostate biopsy ; 2 ) within 30 day discontinuation finasteride ; 3 ) within 90 day discontinuation dutasteride . Has complete baseline healthrelated quality life assessment Extended Prostate Cancer Index Composite questionnaire ( EPIC26 ) Has history physical examination ( include digital rectal examination formal morbidity assessment via ACE27 ) within 60 day Morbidity score ( via ACE27 ) none ( 0 ) , mild ( 1 ) moderate ( 2 ) Willing able use adequate contraception protocol treatment 3 month completion protocol treatment Invasive ( carcinoma situ allow ) solid hematologic malignancy ( prostate cancer , basal squamous skin cancer ) last 5 year Prior prostatectomy cryotherapy prostate Prior radiotherapy prostate lower pelvis Prior concurrent cytotoxic chemotherapy prostate cancer ( prior chemotherapy different cancer allow ) Implanted hardware near plan target volume would prohibit appropriate treatment plan treatment delivery investigator 's opinion</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Stereotactic body radiotherapy</keyword>
	<keyword>Radiosurgery</keyword>
	<keyword>Intensity-modulated radiotherapy</keyword>
	<keyword>SBRT</keyword>
	<keyword>IMRT</keyword>
	<keyword>Early-stage prostate cancer</keyword>
	<keyword>Low-risk prostate cancer</keyword>
	<keyword>Intermediate-risk prostate cancer</keyword>
	<keyword>Intraprostatic lesion</keyword>
	<keyword>IPL</keyword>
</DOC>